Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN6569 + Cemiplimab in Advanced Solid Tumors
NCT04465487Phase 1Terminated
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Oct 2020
- Primary completion
- Feb 2025
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of regn6569 in solid tumor and head and neck squamous cell carcinoma (HNSCC) (3 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Incidence of Dose-Limited Toxicities up to 42 days, Incidence and Severity of Treatment Emergent Adverse Events and 5 more. Started Oct 2020; status: terminated.
02
Drugs
regn6569
03
Conditions
solid tumorhead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04465487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04465487.